CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup-Reference-Cited by-同舟云学术

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Published:2020-02-11 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Aasebø Kristine,Dragomir Anca,Sundström Magnus,Mezheyeuski Artur,Edqvist Per-Henrik,Eide Geir Egil,Ponten Fredrik,Pfeiffer Per,Glimelius Bengt,Sorbye Halfdan

Funder

Akademiska Sjukhuset

Cancerfonden

Kreftforeningen

Universitetet i Bergen

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference35 articles.

1. Global patterns and trends in colorectal cancer incidence and mortality;Arnold;Gut,2017

2. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

3. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer;Sorbye;Ann Oncol,2013

4. Recent changes in overall survival of real-life stage IV colorectal cancer patients;Hamers;J Clin Oncol,2019

5. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas;Werling;Am J Surg Pathol,2003

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study;ESMO Open;2024-08

2. Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer;Scientific Reports;2024-07-30

3. The prognostic impact of Caudal-Type Homologous Transcription Factor-2 (CDX2) expression in duodenal cancer patients;2024-07-01

4. AI-Enhanced RAIN Protocol: A Systematic Approach to Optimize Drug Combinations for Rectal Neoplasm Treatment;2024-06-02

5. Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models;Translational Oncology;2024-06